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Purpose
Identification of biomarkers to predict recurrence risk is essential to improve adjuvant treat-
ment strategies in stage II/III gastric cancer patients. This study evaluated biomarkers for
predicting survival after surgical resection. 
Materials and Methods
This post-hoc analysis evaluated patients from the CLASSIC trial who underwent D2 gas-
trectomy with or without adjuvant chemotherapy (capecitabine plus oxaliplatin) at the Yonsei
Cancer Center. Tumor expressions of thymidylate synthase (TS), excision repair cross-com-
plementation group 1 (ERCC1), and programmed death-ligand 1 (PD-L1) were evaluated
by immunohistochemical (IHC) staining to determine their predictive values.
Results
Among 139 patients, IHC analysis revealed high tumor expression of TS (n=22, 15.8%),
ERCC1 (n=23, 16.5%), and PD-L1 (n=42, 30.2%) in the subset of patients. Among all 
patients, high TS expression tended to predict poor disease-free survival (DFS; hazard ratio
[HR], 1.80; p=0.053), whereas PD-L1 positivity was associated with favorable DFS (HR,
0.33; p=0.001) and overall survival (OS; HR, 0.38; p=0.009) in multivariate Cox analysis.
In the subgroup analysis, poor DFS was independently predicted by high TS expression (HR,
2.51; p=0.022) in the adjuvant chemotherapy subgroup (n=66). High PD-L1 expression
was associated with favorable DFS (HR, 0.25; p=0.011) and OS (HR, 0.22; p=0.015) only
in the surgery-alone subgroup (n=73). The prognostic impact of high ERCC1 expression was
not significant in the multivariate Cox analysis.     
Conclusion
This study shows that high TS expression is a predictive factor for worse outcomes on
capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favor-
able prognostic factor in locally advanced gastric cancer patients.
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Introduction
The radical gastrectomy with D2 node dissection is a stan-
dard procedure in Asian countries that has significantly 
improved patient survival [1]. Nevertheless, locally advan-
ced gastric cancer has a wide range of clinical outcomes after
surgery, influenced by many factors [2,3]. A series of geno-
mic profiling studies have also revealed considerable hetero-
geneity in gastric cancers, which can be classified into several
subtypes on the basis of microsatellite instability, Epstein-
Barr virus infection and chromosomal instability [4,5]. Each
subtype has distinct survival outcomes, which suggests that
innate biological attributes noticeably affect the prognosis of
patients with gastric cancer [4]. Therefore, reliable biomark-
ers are needed to predict recurrence in gastric cancer pati-
ents.
Adjuvant chemotherapy after surgery, such as S-1 mono-
therapy or capecitabine plus oxaliplatin therapy, decreases
recurrence and mortality among East Asian patients with 
locally advanced stage II-III gastric cancer [6-8]. Previous
studies have also identified several metabolic enzymes that
are involved in the response to chemotherapy. For example,
thymidylate synthase (TS) catalyzes the conversion of dUMP
to dTMP and plays a pivotal role in DNA biosynthesis and
repair. TS activity in tumor tissues may influence the respon-
se to fluoropyrimidine-based chemotherapy, including TS-1
and capecitabine [9,10]. Excision repair cross-complementa-
tion group 1 (ERCC1) is another important enzyme that is 
involved in a rate-limiting step during nucleotide excision
repair and double-strand DNA repair. Previous studies 
indicated that non-small cell lung cancers with high ERCC1
expression are resistant to platinum-based chemotherapy
[11,12]. Based on these results, we suspect that expression of
TS and ERCC1 may help predict response to adjuvant
chemotherapy using capecitabine plus oxaliplatin among 
patients with gastric cancer. 
The immune checkpoint pathway that involves program-
med cell death-1 (PD-1) and its ligand (PD-L1) plays a major
role in the immune evasion processes of malignant tumors
[13]. Accumulating evidence suggests that PD-1 blockade
using a monoclonal antibody is active in gastric cancers that
express PD-L1 and the earliest clinical trial revealed an over-
all response rate of 22% in recurrent or metastatic gastric can-
cer patients [14]. Tumor expression of PD-L1 is associated
with patient prognosis in many cancers [15,16] and several
studies have indicated that PD-L1 has prognostic value in
gastric cancer [17-20]. 
The present study involved a post-hoc analysis of patients
with gastric cancer who were enrolled in a landmark adju-
vant chemotherapy trial (the CLASSIC trial) [7,8] that evalu-
ated the efficacy of capecitabine plus oxaliplatin after D2
gastrectomy. We also performed a subgroup analysis to eval-
uate the predictive values of each potential biomarker in the
adjuvant chemotherapy plus surgery group (“the adjuvant
chemotherapy group”) and in the surgery along group. 
Materials and Methods
1. Study population and ethical statement
This post-hoc analysis evaluated patients with gastric can-
cer who were enrolled in a phase III open-label multi-center
randomized controlled trial (the CLASSIC trial) that com-
pared capecitabine plus oxaliplatin after D2 gastrectomy ver-
sus D2 gastrectomy alone. A consecutive subset of the
CLASSIC trial participants (n=144, enrolled between May
2006 and April 2009 at the Yonsei Cancer Center) were selec-
ted for the present study. All patients had undergone radical
gastrectomy with D2 lymph node dissection for their pri-
mary gastric tumors and were randomized to receive either
adjuvant chemotherapy or surgery alone. Among the 144 
patients, the present study excluded five patients because 
immunohistochemical (IHC) analysis of their tumors was not
technically feasible. Thus, the present study evaluated 139
patients with a median follow-up duration of 98.5 months at
April 2017. Data regarding age, sex, tumor stage, and patho-
logical findings were retrospectively obtained from data-
bases of the CLASSIC trial and Severance Hospital. Tumors
were staged according to the sixth version of the American
Joint Committee on Cancer (AJCC) criteria. 
2. Immunohistochemistry
Stored formalin-fixed paraffin-embedded tissues from the
patients’ primary gastric tumors were collected, and a micro-
tome was used to create 4-µm sections for IHC. The presence
of carcinoma in the sections was confirmed using a patho-
logical review of hematoxylin and eosin staining results. The
sections were de-paraffinized and rehydrated using xylene
and ethanol, and antigen retrieval was performed using a tar-
get retrieval solution (citrate pH 6; Agilent, Santa Clara, CA).
The IHC staining was performed using primary antibodies
against TS (TS106, Thermo Scientific, Waltham, MA), ERCC1
(8F1, Abcam, Cambridge, UK), and PD-L1 (SP142, Spring
Bioscience, Pleasanton, CA) with chromogenic detection that
was performed using a peroxidase/DAB kit (EnVision 
Detection Systems, Agilent). We used the weighted his-
toscore method (H-score) to determine the TS and ERCC1 
expression scores. For TS and ERCC1 expression, sections of
HeLa cell blocks and the normal tonsil were used as positive
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controls for TS and ERCC1 antibody, respectively. Mouse
IgG2a (Dako Cytomation, Glustrup, Denmark), excluding
the primary antibody, was used as the negative control. For
TS and ERCC1 expression, the staining intensity of tumor
cells was classified as 0 (negative), 1 (light brown), 2 (brown),
or 3 (dark brown). The protein expression was interpreted
using the histoscore, calculated by the multiplying staining
intensity and proportion of stained tumor cells as follows:
(0% of negative cells)+(1% of light brown cells)+(2% of
brown cells)+(3% of dark brown cells) [21]. For example, a
specimen with 20% of cells classified as an intensity of 3, 20%
as 2, 30% as 1, and 30% as 0 (unstained cells) would have a
histoscore of (320)+(220)+(130)=130. Histoscores range
from 0 to 300. Tumors with H-score  100 were defined as
having high TS or ERCC1 expression, whereas tumors with
H-score < 100 were defined as having low TS or ERCC1 
expression. The proportion of membranous PD-L1 staining
on tumor cells or intercalated inflammatory cells was evalu-
ated, and tumors with  1% of cells expressing PD-L1 were
defined as PD-L1-positive tumors [22]. Representative IHC
images for TS, ERCC1, and PD-L1 are shown in Fig. 1. All
pathological reviews were performed by pathology experts
who were blinded to the patients’ clinical and survival data.
3. Statistical analysis
Fisher exact test or the chi-square test was used to compare
clinical variables according to treatment group and biomar-
ker status. Disease-free survival (DFS) was defined as the
time from surgery to recurrence, second primary cancer, or
death, and overall survival (OS) was defined as time from
the date of the operation to the date of death from any cause.
Data for patients who had not had an event were censored
as of the date of final observation. DFS and OS after surgical
resection were compared in each biomarker group using the
Kaplan-Meier method and log-rank test. Cox regression
Fig. 1.  Representative images of positive and negative staining results for TS, ERCC1, and PD-L1 in the primary gastric 
tumors. TS, thymidylate synthase; ERCC1, excision repair cross-complementation group 1; PD-L1, programmed death-ligand
1. Scale bars=100 µm. 
High
TS
ERCC1
PD-L1 
Low
Positive Negative
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analysis was performed to determine the hazard ratios (HR)
and 95% confidence intervals (CIs) for DFS and OS according
to the clinical variables and biomarkers. The biomarkers’ val-
ues for predicting DFS and OS were estimated using multi-
variate Cox regression analysis, which was adjusted for the
T category and N category. Differences were considered sta-
tistically significant at two-tailed p-values < 0.05, and all data
were analyzed using IBM SPSS software ver. 24.0 (IBM
Corp., Armonk, NY). GraphPad Prism software (GraphPad
Software Inc., San Diego, CA) was used to create the Kaplan-
Meier curves. 
4. Ethical statement
The present study’s protocol was approved by the institu-
tional review board (IRB) of Severance Hospital (4-2017-
1111). This study is the retrospective post-hoc analysis of
CLASSIC trial, and the informed consent for CLASSIC trial
Cancer Res Treat. 2019;51(2):819-831
Table 1.  Baseline characteristics in the two treatment groups
Variable Total Chemotherapy+ Surgery only p-value(n=139) surgery group (n=66) group (n=73)
Sex
Male 97 (69.8) 43 (65.2) 54 (74.0) 0.258
Female 42 (30.2) 23 (34.8) 19 (26.0)
Age (yr)
< 60 92 (66.2) 45 (68.2) 47 (64.4) 0.636
 60 47 (33.8) 21 (31.8) 26 (35.6)
T category
1 3 (2.2) 2 (3.0) 1 (1.4) 0.124a)
2 52 (37.4) 19 (28.8) 33 (45.2)
3 83 (59.7) 44 (66.7) 39 (53.4)
4 1 (0.7) 1 (1.5) 0 (
N category
0 16 (11.5) 8 (12.1) 8 (11.0) 0.699a)
1 83 (59.7) 40 (60.6) 43 (58.9)
2 40 (28.8) 18 (27.3) 22 (30.1)
Histology
Non-SRC 102 (73.4) 52 (78.8) 50 (68.5) 0.170
SRC 37 (26.6) 14 (21.2) 23 (31.5)
Gradeb)
WD/MD 80 (57.6) 34 (51.5) 46 (63.0) 0.171
PD/UD 59 (42.4) 32 (48.5) 27 (37.0)
Lauren type
Intestinal 47 (33.8) 23 (34.8) 24 (32.9) 0.464
Diffuse 79 (56.8) 39 (59.1) 40 (54.8)
Mixed 13 (9.4) 4 (6.1) 9 (12.3)
LVI
Negative 52 (37.4) 24 (36.4) 28 (38.4) 0.808
Positive 87 (62.6) 42 (63.6) 45 (61.6)
PNI
Negative 46 (33.1) 21 (31.8) 25 (34.2) 0.761
Positive 93 (66.9) 45 (68.2) 48 (65.8)
Operation
Subtotal 89 (64.0) 37 (56.1) 52 (71.2) 0.063
Total 50 (36.0) 29 (43.9) 21 (28.8)
Values are presented as number (%). SRC, signet ring cell carcinoma; WD/MD, well differentiated/moderately differentiated;
PD/UD, poorly differentiated or undifferentiated; LVI, lymphovascular invasion; PNI, perineural invasion. a)The p-value
was calculated by Mantel-Haenszel linear-by-linear association test, b)Well differentiated or moderate differentiated tumors
are classified as low grade, and poorly differentiated tumors are classified as high grade.
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enrollment was obtained from all patients. The requirement
for additional informed consent for this study was waived
by the IRB because this study was performed more than 5
years after the CLASSIC trial enrollment and acquisition of
the tumor tissue.
Results
1. Baseline patient characteristics
The post-hoc analysis evaluated data from 139 patients with
stage II-III gastric cancer who underwent radical gastrectomy
Min Hwan Kim, Prognostic IHC Markers in CLASSIC Trial
Table 2.  Baseline characteristics according to TS, ERCC1, and PD-L1 expression
TS TS ERCC1 ERCC1 PD-L1 PD-L1
Variable low high p-value low high p-value low high p-value
(n=117) (n=22) (n=116) (n=23) (n=97) (n=42)
Sex
Male 80 (82.5) 17 (17.5) 0.404 89 (91.8) 8 (8.2) < 0.001 68 (70.1) 29 (29.9) 0.901
Female 37 (88.1) 5 (11.9) 27 (64.3) 15 (35.7) 29 (69.0) 13 (31.0)
Age (yr)
< 60 76 (82.6) 16 (17.4) 0.480 73 (79.3) 19 (20.7) 0.091 65 (70.7) 27 (29.3) 0.755
 60 41 (87.2) 6 (12.8) 43 (91.5) 4 (8.5) 32 (68.1) 15 (31.9)
T category
T1 3 (100) 0 ( 0.410a) 3 (100) 0 ( 0.312a) 1 (33.3) 2 (66.7) > 0.999a)
T2 45 (86.5) 7 (13.5) 45 (86.5) 7 (13.5) 39 (75.0) 13 (25.0)
T3 68 (81.9) 15 (18.1) 67 (80.7) 16 (19.3) 56 (67.5) 27 (32.5)
T4 1 (100) 0 ( 1 (100) 0 ( 1 (100) 0 (
N category
N0 14 (87.5) 2 (12.5) 0.404a) 12 (75.0) 4 (25.0) 0.139a) 15 (93.8) 1 (6.3) 0.003a)
N1 71 (85.5) 12 (14.5) 68 (81.9) 15 (18.1) 60 (72.3) 23 (27.7)
N2 32 (80.0) 8 (20.0) 36 (90.0) 4 (10.0) 22 (55.0) 18 (45.0)
Histology
Non-SRC 85 (83.3) 17 (16.7) 0.653 90 (88.2) 12 (11.8) 0.012 65 (63.7) 37 (36.3) 0.010
SRC 32 (86.5) 5 (13.5) 26 (70.3) 11 (29.7) 32 (86.5) 5 (13.5)
Grade
WD/MD 69 (86.3) 11 (13.8) 0.435 69 (86.3) 11 (13.8) 0.301 56 (70.0) 24 (30.0) 0.949
PD/UD 48 (81.4) 11 (18.6) 47 (79.7) 12 (20.3) 41 (69.5) 18 (30.5)
Lauren type
Intestinal 38 (80.9) 9 (19.1) 0.649 45 (95.7) 2 (4.3) 0.001 25 (53.2) 22 (46.8) 0.003
Diffuse 67 (84.8) 12 (15.2) 58 (73.4) 21 (26.6) 64 (81.0) 15 (19.0)
Mixed 12 (92.3) 1 (7.7) 13 (100) 0 ( 8 (61.5) 5 (38.5)
LVI
Negative 43 (82.7) 9 (17.3) 0.712 38 (73.1) 14 (26.9) 0.017 41 (78.8) 11 (21.2) 0.072
Positive 74 (85.1) 13 (14.9) 78 (89.7) 9 (10.3) 56 (64.4) 31 (35.6)
PNI
Negative 39 (84.8) 7 (15.2) 0.890 40 (87.0) 6 (13.0) 0.479 30 (65.2) 16 (34.8) 0.410
Positive 78 (83.9) 15 (16.1) 76 (81.7) 17 (18.3) 67 (72.0) 26 (28.0)
Operation
Subtotal 74 (83.1) 15 (16.9) 0.658 79 (88.8) 10 (11.2) 0.025 64 (71.9) 25 (28.1) 0.466
Total 43 (86.0) 7 (14.0) 37 (74.0) 13 (26.0) 33 (66.0) 17 (34.0)
Values are presented as number (%). The percentage in parenthesis indicates the proportion of biomarker expression in each
row. TS, thymidylate synthase; ERCC1, excision repair cross-complementation group 1; PD-L1, programmed death-ligand
1; SRC, signet ring cell carcinoma; WD/MD, well differentiated/moderately differentiated; PD/UD, poorly differentiated
or undifferentiated; LVI, lymphovascular invasion; PNI, perineural invasion. a)The p-value was calculated by Mantel-Haen-
szel linear-by-linear association test. 
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Fig. 2.  Kaplan-Meier curves for DFS and OS according to TS, ERCC1, and PD-L1 expression among all 139 patients. The
DFS and OS outcomes were compared using the log-rank test. DFS, disease-free survival; OS, overall survival; TS, thymidy-
late synthase; ERCC1, excision repair cross-complementation group 1; PD-L1, programmed death-ligand 1.
with or without adjuvant chemotherapy (Table 1). Eighty-
five patients (64%) underwent subtotal gastrectomy and 50
patients (36%) underwent total gastrectomy. The patients
were randomized to the adjuvant chemotherapy subgroup
(n=66) or the surgery alone subgroup (n=73). In the adjuvant
chemotherapy subgroup, 52 patients (80.3%) completed eight
cycles of capecitabine plus oxaliplatin chemotherapy and the
remaining patients stopped adjuvant chemotherapy because
of consent withdrawal (n=7), chemotherapy toxicity (n=3),
or disease recurrence during chemotherapy (n=4). In accor-
dance with previous reports regarding this population, the
two treatment groups did not have any significant differ-
ences in their clinical variables and histological findings
(Table 1). 
2. Clinicopathological characteristics according to TS,
ERCC1, and PD-L1 status
All tumors were analyzed for TS and ERCC1 expression,
and the patients were dichotomized according to the IHC
score (H-score  100 vs. H-score < 100). There were no dif-
ferences in the clinicopathological characteristics of the pati-
ents with low TS expression and high TS expression (Table 2).
Compared to cases with low ERCC1 expression, cases with
high ERCC1 expression were more likely to involve female
patients (p < 0.001), signet ring cell carcinoma (p=0.012), the
diffuse type based on the Lauren classification (p=0.001), no
lymphovascular invasion (p=0.017), and total gastrectomy
(p=0.025). Positive tumor expression of PD-L1 was associated
with non-signet ring cell carcinoma (p=0.01), the intestinal
type based on the Lauren classification (p=0.003), and N2 cat-
egory disease (p=0.003). There were no significant associa-
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Variable Category
Univariate Multivariatea)
HR 95% CI p-value HR 95% CI p-value
Disease-free survival
Thymidylate synthase High vs. low (reference) 1.86 1.02-3.37 0.042 1.80 0.99-3.28 0.053
ERCC1 High vs. low (reference) 1.33 0.72-2.45 0.364 1.37 0.74-2.55 0.320
PD-L1  1% vs. < 1% (reference) 0.37 0.19-0.73 0.004 0.33 0.17-0.65 0.001
Overall survival
Thymidylate synthase High vs. low (reference) 1.64 0.84-3.19 0.145 1.58 0.8-3.07 0.181
ERCC1 High vs. low (reference) 1.28 0.66-2.49 0.470 1.24 0.63-2.42 0.540
PD-L1  1% vs. < 1% (reference) 0.42 0.21-0.86 0.018 0.38 0.18-0.78 0.009
Table 4. Prognostic impact of biomarkers in univariate and multivariate Cox regression analysis in all patients
HR, hazard ratio; 95% CI, 95% confidence interval; ERCC1, excision repair cross-complementation group 1; PD-L1, pro-
gramed cell death ligand 1. a)Multivariable Cox regression analysis adjusted for T category (T3-T4 vs. T1-T2) and N category
(N2 vs. N0-N1).
Variable Category
Disease-free survival Overall survival
HR 95% CI p-value HR 95% CI p-value
Age  60 vs. < 60 (reference) 1.12 0.66-1.89 0.676 1.07 0.60-1.89 0.829
Sex Female vs. male (reference) 0.73 0.41-1.29 0.275 0.77 0.42-1.43 0.410
AJCC stage Stage III vs. stage II (reference) 1.39 0.83-2.35 0.216 1.55 0.87-2.74 0.136
T category T3-T4 vs. T1-T2 (reference) 1.67 0.97-2.87 0.064 1.82 1.00-3.31 0.051
N category N2 vs. N0-N1 (reference) 1.63 0.96-2.78 0.070 1.46 0.82-2.60 0.203
Grade PD/UD vs. WD/MD (reference) 1.06 0.64-1.75 0.832 1.07 0.62-1.85 0.815
Lauren type Diffuse vs. intestinal/mixed (reference) 1.16 0.70-1.94 0.561 1.33 0.76-2.33 0.312
Table 3. Univariate Cox regression analysis of clinical variables for disease-free survival and overall survival of patients
HR, hazard ratio; 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; WD/MD, well differenti-
ated/moderately differentiated; PD/UD, poorly differentiated or undifferentiated.
VOLUME 51 NUMBER 2 APRIL 2019  825
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Fig. 3.  Kaplan-Meier curves for DFS and OS according to TS, ERCC1, and PD-L1 expression in 66 patients who received 
adjuvant chemotherapy. The DFS and OS outcomes were compared using the log-rank test. DFS, disease-free survival; OS,
overal survival; TS, thymidylate synthase; ERCC1, excision repair cross-complementation group 1; PD-L1, programmed
death-ligand 1.
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Fig. 4.  Kaplan-Meier curves for DFS and OS according to TS, ERCC1, and PD-L1 expression in 73 patients who only under-
went surgery. The DFS and OS outcomes were compared using the log-rank test. DFS, disease-free survival; OS, overall sur-
vival; TS, thymidylate synthase; ERCC1, excision repair cross-complementation group 1; PD-L1, programmed death-ligand
1.
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tions between the TS, ERCC1, and PD-L1 expression statuses
in the patients’ tumors (S1 Table).
3. Values of TS, ERCC1, and PD-L1 expression for predict-
ing DFS and OS among all patients
The values of TS, ERCC1, and PD-L1 expression for pre-
dicting DFS and OS after surgical resection were evaluated
among all patients. Compared to low TS expression, high TS
expression was associated with significantly worse DFS
(p=0.039) but not OS (p=0.141) (Fig. 2). In contrast, ERCC1
expression was not associated with DFS or OS. Positive PD-L1
expression was associated with significantly better DFS
(p=0.003) and OS (p=0.015) (Fig. 2). In the univariate Cox
analysis of DFS and OS (Table 3), higher T category and N
category tended to predict poorer DFS (T category, p=0.064;
N category, p=0.070) and poorer OS (T category, p=0.051; N
category, p=0.203). In the multivariate Cox analysis, which
were adjusted for T category and N category (Table 4), high
TS expression tended to be associated with poorer DFS (HR,
1.80; 95% CI, 0.99 to 3.28; p=0.053) but not poorer OS. Positive
PD-L1 expression independently predicted favorable DFS
(HR, 0.33; 95% CI, 0.17 to 0.65; p=0.001) and favorable OS
(HR, 0.38; 95% CI, 0.18 to 0.78; p=0.009). The expression of
ERCC1 was not associated with DFS or OS in the Cox regres-
sion analysis.
4. Values of the biomarkers for predicting survival in the
adjuvant chemotherapy and surgery alone subgroups
In the adjuvant chemotherapy subgroup, high TS expres-
sion was associated with significantly worse DFS (p=0.029)
and OS (p=0.009), but it was not associated with survival in
the surgery alone subgroup (Figs. 3 and 4). Similarly, high
ERCC1 expression in the adjuvant chemotherapy subgroup
was associated with significantly worse DFS (p=0.029) 
(Fig. 3). In the surgery alone subgroup, positive PD-L1 expre-
ssion was associated with favorable DFS (p=0.010) and 
favorable OS (p=0.015) (Fig. 4), with the DFS and OS values
being non-significantly higher than in the adjuvant chemo-
therapy subgroup (DFS, p=0.141; OS, p=0.354) (Fig. 3). In the
multivariate Cox analysis, which was adjusted for T category
and N category (Table 5), high TS expression in the adjuvant
chemotherapy subgroup independently predicted worse
DFS (HR, 2.51; 95% CI, 1.14 to 5.52; p=0.022) and worse OS
(HR, 3.34; 95% CI, 1.42 to 7.87; p=0.006). However, high
ERCC1 expression showed a trend of being associated with
poor DFS, but it was not statistically significant on multivari-
ate Cox analysis (HR, 2.08; 95% CI, 0.94 to 4.58; p=0.070). In
the surgery alone subgroup, high PD-L1 expression signifi-
cantly predicted favorable DFS (HR, 0.25; 95% CI, 0.09 to
0.73; p=0.011) and favorable OS (HR, 0.22; 95% CI, 0.07 to
0.57; p=0.015). 
Discussion
The present study evaluated whether the expression of TS,
ERCC1, or PD-L1 could predict survival after primary gas-
trectomy with or without adjuvant chemotherapy in gastric
cancer patients from single center study of CLASSIC trial.
The results indicated that high expression of TS significantly
predicted poor DFS and OS in the adjuvant chemotherapy
subgroup but not in the surgery only subgroup. PD-L1 
expression predicted significantly better DFS and OS in the
surgery alone subgroup but not in the adjuvant chemother-
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Variable Category
Adjuvant chemotherapy group Surgery only group
HR 95% CI p-value HR 95% CI p-value
Disease-free survival
Thymidylate synthase High vs. low (reference) 2.51 1.14-5.52 0.022 0.95 0.32-2.77 0.918
ERCC1 High vs. low (reference) 2.08 0.94-4.58 0.070 0.78 0.23-2.64 0.686
PD-L1  1% vs. < 1% (reference) 0.43 0.17-1.10 0.077 0.25 0.09-0.73 0.011
Overall survival
Thymidylate synthase High vs. low (reference) 3.34 1.42-7.87 0.006 0.39 0.09-1.68 0.205
ERCC1 High vs. low (reference) 1.68 0.71-4.01 0.239 0.87 0.25-2.98 0.824
PD-L1  1% vs. < 1% (reference) 0.58 0.23-1.48 0.252 0.22 0.07-0.75 0.015
Table 5. Multivariate Cox regression analysis of biomarkers in the adjuvant chemotherapy group and surgery only group
All multivariate Cox regression analysis were adjusted for T category (T3-T4 vs. T1-T2) and N category (N2 vs. N0-N1). HR,
hazard ratio; 95% CI, 95% confidence interval; ERCC1, excision repair cross-complementation group 1; PD-L1, programed
cell death ligand 1.
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apy subgroup. Patients with high ERCC1 expression showed
significantly shorter DFS in the adjuvant chemotherapy
group compared to that of patients with low expression, but
the prognostic impact of ERCC1 expression on DFS did not
show statistical significance in the multivariate Cox regres-
sion analysis (p=0.070). These results suggest that high expre-
ssion of TS predicts a poor response to adjuvant chemothe-
rapy using capecitabine plus oxaliplatin, while PD-L1 expre-
ssion is a general prognostic marker that predicts favorable
tumor behavior. Therefore, these biomarkers may be useful
for predicting recurrence risk and selecting appropriate ther-
apeutic interventions after surgical resection of gastric can-
cer. 
The prognosis of gastric cancer patients varies from patient
to patient after surgery and adjuvant chemotherapy, which
highlights the need for reliable biomarkers in this setting
[6,8]. Furthermore, survival outcomes remain poor for recur-
rent or metastatic gastric cancer [23], although several novel
agents have been approved as standard treatments, such as
trastuzumab [24] and ramucirumab [25]. Therefore, biomark-
ers that can facilitate stratification of recurrence risk could
help guide the selection of adjuvant chemotherapy. For exam-
ple, a study reported that S-1 adjuvant chemotherapy pro-
vides more clinical benefit in gastric cancers with high TS
and dihydropyrimidine dehydrogenase enzyme expression,
and patients with carboxylesterase 2 gene polymorphisms
were reported to show high capecitabine toxicity and anti-
tumor response [10,26]. In addition, platinum-based che-
motherapy agents are commonly combined with fluoropyri-
midines for treating gastric cancer, and ERCC1 expression
and XRCC1 and XPD polymorphisms were reported as sig-
nificant prognostic factors in patients treated with platinum-
based chemotherapy [12,27]. Previous studies have examined
the prognostic significance of TS and ERCC1 expression in
patients with gastric cancer who received adjuvant chemo-
therapy [28-31], although those studies were limited by their
small sample size and retrospective design. Moreover, there
is no validated marker for predicting response to adjuvant
chemotherapy using capecitabine plus oxaliplatin. Our results
suggest that high expression of TS could predict a poor 
response to this adjuvant chemotherapy among patients with
gastric cancer. Therefore, alternative strategies with different
chemotherapeutic agents should be considered for patients
with high TS expression. It might also be useful to consider
novel biological agents that can modulate TS activity.
The immune checkpoint pathway involving PD-1/PD-L1
plays a major role in the immune evasion mechanism of 
malignant tumors. Two monoclonal antibodies that block
this pathway (pembrolizumab and nivolumab) have notable
anti-tumor activity in patients with gastric cancer [14,32]. 
Interestingly, some studies have indicated that tumor expres-
sion of PD-L1 is associated with a favorable prognosis
[17,20], while other studies have suggested that it is associ-
ated with a poor prognosis [18,19]. These contradictory 
results may be attributed to differences in the primary anti-
body to PD-L1, the IHC staining procedure, the PD-L1 scor-
ing system, and the patients who were evaluated. Never-
theless, our results indicate that PD-L1 expression independ-
ently predicts a favorable prognosis in curatively resected
gastric cancer patients without adjuvant chemotherapy. The
major mechanism for PD-L1 expression is mediated by inter-
feron  in inflamed tumor tissues. Increased PD-L1 expres-
sion indicates an active T-cell response in the tumor tissues,
which leads to favorable tumor behavior and clinical out-
comes. In our study, the PD-L1 expression was not associated
with survival in the adjuvant chemotherapy group. Two clin-
ical trials are currently testing the efficacy of adjuvant ther-
apy using anti-PD-1 blockade in gastric cancer after surgical
resection (CheckMate-577 [NCT02743494] and KEYNOTE-
585 [NCT03221426]), and their results should help clarify the
predictive role of PD-L1 expression in the adjuvant setting. 
The strength of the present study lies in its post-hoc analysis
of prospectively collected data from patients with gastric
cancer who were selected for a prospective trial and fol-
lowed-up for a prolonged period of time. In addition, the
present study included a sub-analysis of each treatment arm,
which allowed us to clarify the prognostic value of the bio-
markers among patients who received adjuvant chemother-
apy or surgery alone. 
However, the present study also has several limitations.
First, the data were obtained from patients who participated
in the CLASSIC trial at a single center, which limited the
sample size. In addition, the portion of patients with high TS
expression was small. Despite the prognostic significance of
this marker, the result might be attributed to chance. To find
the statistical significance, we performed a bootstrapping
analysis using 1,000 re-samplings. The number of null hypo-
thesis rejections was moderate to high (range, 276 to 851, data
not shown). Therefore, the results for our prognostic factors
were statistically significant, although the possibility that the
results were attributed to chance could not be ruled out com-
pletely. In addition, the prognostic impact of AJCC stage was
not statistically significant in our study population. How-
ever, the pathologic T category and N category were corre-
lated with a poor prognosis. In addition, stage III patients
showed shorter DFS and OS than stage II patients, although
the difference was not statistically significant because of the
small sample size (S2 Fig.). Therefore, more research with
larger sample sizes is needed to validate our findings. Sec-
ond, further studies are also needed to validate the cut-off
criteria for interpreting the IHC results with the same pri-
mary antibodies that were used.
In conclusion, we performed a post-hoc analysis of pro-
spectively collected clinical trial data to evaluate whether TS,
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ERCC1, and PD-L1 expression could predict survival among
patients with gastric cancer. The results revealed that high
tumor expression of TS predicted poor survival after adju-
vant chemotherapy using capecitabine plus oxaliplatin,
whereas PD-L1 expression was associated with favorable
DFS and OS in the surgery only subgroup. We suggest that
these biomarkers may be useful to perform stratification of
recurrence risk after surgical resection of locally advanced
gastric cancer and may facilitate the design of customized
adjuvant therapies for individual patients. 
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